検索結果

adquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces that the orphan drug designation to the in-house developed compound having the development code SJP-0008 ...

adquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces that the orphan drug designation to the in-house developed compound having the development code SJP-0008 ...

MytearV | OTC Products, etc. | Products | SENJU Pharmaceutical

Category 2 OTC medicines Mytear® V Resolves redness of the eye and provides healthy and clear eyes. CHARACTERISTICS Compounded with "tetrahydrozoline hydrochloride", a component to relieve r...

研究開発の取り組み | 千寿製薬株式会社

earch and Development System R & D Pipeline Clinical trial information Publications Meetings of the Minds Business Collaboration Inquiries licensing★senju.co.jp* When contacting us by e-mail, plea...

Product Development Policy | Research & Development | SENJU Pharmaceutica

Corporate Strategy DivisionProduct Planning DepartmentDirectorYasunobu Maenaka With the management philosophy of “Good Company” and a company that shapes “Beyond eyesight,” we have developed products ...